Mesoblast’s business model is very similar to classical pharmaceutical drug development: to deliver effective products with low manufacturing costs of goods and high margins.
This has been achieved as a result of two technical advantages that are unique to the patented stem cell technology- the ability of the cells to be greatly expanded and their lack of immunogenicity when used from one donor to treat many unrelated recipients.
The outcome is to generate industrially scaled-up allogeneic or ‘off-the-shelf’ products for use in thousands of patients from a small amount of starting material obtained from a single donor.
Like pharmaceutical drugs, Mesoblast’s allogeneic stem cell products are batched, with each batch being highly reproducible and consistent to ensure product safety and effectiveness. Equally as important is that ‘off-the-shelf’ products will be available for immediate use at hospitals for patients with acute orthopaedic trauma or cardiac events.
Unlike pharmaceuticals, which are generally used to treat a single disease or condition, Mesoblast’s proprietary adult stem cells can be used in a broad range of indications where replacement of damaged tissue is required.
Consequently, Mesoblast’s adult stem cell products may be beneficial in heart muscle and blood vessel restoration, diseases of the central nervous system, eye diseases, expansion of bone marrow, treating bone fractures, cartilage replacement, diabetes and many more applications.